{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:04:30Z","timestamp":1779242670810,"version":"3.51.4"},"reference-count":152,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.leukres.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T03:38:17Z","timestamp":1438832297000},"page":"1006-1019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Vaccination strategies in lymphoproliferative disorders: Failures and successes"],"prefix":"10.1016","volume":"39","author":[{"given":"A.","family":"Allegra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gerace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Maisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Innao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.08.001_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11912-012-0255-7","article-title":"Active immunotherapy: current state of the art in vaccine approaches for NHL","volume":"14","author":"Palomba","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.leukres.2015.08.001_bib0010","first-page":"37","article-title":"Absence of HLA class I expression by Reed-Sternberg cells","volume":"145","author":"Poppema","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2141.2002.03814.x","article-title":"Major histocompatibility complex abnormalities in non-Hodgkin lymphomas","volume":"119","author":"Dr\u00e9nou","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2015.08.001_bib0025","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1073\/pnas.72.6.2357","article-title":"Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes","volume":"72","author":"Janeway","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2015.08.001_bib0030","first-page":"126","article-title":"Anti-idiotypic therapy of leukemias and lymphomas","volume":"48","author":"Stevenson","year":"1990","journal-title":"Chem. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0035","first-page":"61","article-title":"Therapy of lymphoma directed at idiotypes","volume":"10","author":"Levy","year":"1990","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.leukres.2015.08.001_bib0040","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.168.8.3983","article-title":"Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope","volume":"168","author":"Armstrong","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0045","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1073\/pnas.75.5.2411","article-title":"Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization","volume":"75","author":"Levy","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2015.08.001_bib0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00262-007-0388-y","article-title":"Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma","volume":"57","author":"Neelson","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.leukres.2015.08.001_bib0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.biotechadv.2011.06.020","article-title":"Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech\u2019s challenge","volume":"30","author":"Iurescia","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.leukres.2015.08.001_bib0060","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.molimm.2007.01.010","article-title":"Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner","volume":"44","author":"Lopez-Requena","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/protein\/10.6.731","article-title":"Mammalian cell expression of dimeric small immune proteins (SIP)","volume":"10","author":"Li","year":"1997","journal-title":"Protein Eng."},{"key":"10.1016\/j.leukres.2015.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.gt.3301546","article-title":"Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)\/V(H) determinants","volume":"8","author":"Benvenuti","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.leukres.2015.08.001_bib0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1566523024605654","article-title":"Genetic vaccination for the immunotherapy of B-cell malignancies","volume":"2","author":"Benvenuti","year":"2002","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.leukres.2015.08.001_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-3083.2008.02119.x","article-title":"Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination","volume":"68","author":"Cesco-Gaspere","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0085","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.165.5.2850","article-title":"Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice","volume":"165","author":"Dupuis","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0090","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood.V97.5.1370","article-title":"Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas","volume":"97","author":"Timmerman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0095","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1016\/j.vaccine.2009.05.025","article-title":"Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin","volume":"27","author":"Chen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.leukres.2015.08.001_bib0100","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm0996-1038","article-title":"DNA immunization induces protective immunity against B-cell lymphoma","volume":"2","author":"Syrengelas","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2015.08.001_bib0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5306\/wjco.v2.i6.237","article-title":"Idiotype vaccines for lymphoma: potential factors predicting the induction of immune responses","volume":"2","author":"Inoges","year":"2011","journal-title":"Word J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/10428190802601122","article-title":"Prolonged idiotypic vaccination against follicular lymphoma","volume":"50","author":"Inoges","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2015.08.001_bib0115","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V92.4.1184","article-title":"Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin\u2019s lymphoma without eradicating the malignant clone","volume":"92","author":"Davis","year":"1998","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2015.08.001_bib0120","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJM198506273122602","article-title":"Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies","volume":"312","author":"Meeker","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2015.08.001_bib0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00003","article-title":"Immunotherapy for B-cell lymphoma: current status and prospective advances","volume":"3","author":"Hollander","year":"2012","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.leukres.2015.08.001_bib0130","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1073\/pnas.91.12.5700","article-title":"Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors","volume":"91","author":"Lauritzsen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0135","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2010-02-270199","article-title":"Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma","volume":"116","author":"Strothmeyer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0140","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","article-title":"Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins","volume":"107","author":"Coelho","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2015.08.001_bib0145","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0150","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1074\/jbc.M602690200","article-title":"Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor","volume":"282","author":"Radcliffe","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2015.08.001_bib0155","first-page":"541","article-title":"Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies","volume":"89","author":"Zabalegui","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2015.08.001_bib0160","article-title":"Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins","volume":"11","author":"L\u00f3pez-Requena","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0165","first-page":"1171","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"11","author":"Gocke","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2015.08.001_bib0170","first-page":"4717","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"11","author":"Czerwinski","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0175","first-page":"1503","article-title":"Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients","volume":"11","author":"Abdalla","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1600-0609.1992.tb00040.x","article-title":"Extramedullary progression of multiple myeloma following GM-CSF treatment\u2013grounds for caution?","volume":"11","author":"Celsing","year":"1992","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0185","doi-asserted-by":"crossref","first-page":"14526","DOI":"10.1073\/pnas.1211018109","article-title":"A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity","volume":"109","author":"Ng","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2015.08.001_bib0190","first-page":"2573","article-title":"Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants","volume":"11","author":"Bettua","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0195","first-page":"2174","article-title":"Engineering filamentous phage carriers to improve focusing of antibody responses against peptides","volume":"11","author":"van","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.leukres.2015.08.001_bib0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1479-5876-11-267","article-title":"Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model","volume":"11","author":"Roehnisch","year":"2013","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.leukres.2015.08.001_bib0205","first-page":"215","article-title":"An endogenous immune adjuvant released by necrotic cells for enhancement of DNA vaccine potency","volume":"9","author":"Dorostkar","year":"2012","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0210","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.4049\/jimmunol.161.10.5516","article-title":"Cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines","volume":"161","author":"Wang","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0215","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/jid.2008.125","article-title":"Induction of T-responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic s transfected with amplified tumor mRNA","volume":"128","author":"Ni","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.cgt.7700499","article-title":"Efficient genetic modification of murine dendritic cells by electroporation with mRNA","volume":"9","author":"Van","year":"2002","journal-title":"Cancer Gene Ther."},{"issue":"suppl. 1","key":"10.1016\/j.leukres.2015.08.001_bib0225","first-page":"466","article-title":"clinical trial of sequential dendritic cell, and protein\/adjuvant idiotype vaccines in patients with follicular lymphomas","volume":"98","author":"Hsu","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellimm.2010.02.010","article-title":"Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2\/neu induced protective antitumor immunity in two lines of Her-2\/neu transgenic mice","volume":"263","author":"Saha","year":"2010","journal-title":"Cell Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0235","first-page":"500","article-title":"CD40 is expressed on epithelial ovarian cancer cells and modulates growth","volume":"38","author":"Gallagher","year":"1997","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0240","first-page":"891","article-title":"Endothelial expression of CD40 in renal cell carcinoma","volume":"57","author":"Kluth","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0245","first-page":"2261","article-title":"Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines","volume":"5","author":"Posner","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0250","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2567.2000.00074.x","article-title":"Fortifying B cells with CD154, an engaging tale of many hues","volume":"100","author":"Gordon","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.leukres.2015.08.001_bib0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(97)80078-7","article-title":"Functions of CD40 on B cells, dendritic cells and other cells","volume":"9","author":"van","year":"1997","journal-title":"Curr. Opin. Immunol."},{"issue":"6684","key":"10.1016\/j.leukres.2015.08.001_bib0260","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T helper and a T killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"issue":"6684","key":"10.1016\/j.leukres.2015.08.001_bib0265","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"issue":"6684","key":"10.1016\/j.leukres.2015.08.001_bib0270","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2567.2003.01634.x","article-title":"A potent adjuvant effect of CD40 antibody attached to antigen","volume":"109","author":"Barr","year":"2003","journal-title":"Immunology"},{"issue":"25\u201326","key":"10.1016\/j.leukres.2015.08.001_bib0280","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1016\/j.vaccine.2004.02.043","article-title":"CD40 antibody as an adjuvant induces enhanced T cell responses","volume":"22","author":"Carlring","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.leukres.2015.08.001_bib0285","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1182\/blood-2011-05-355461","article-title":"Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice","volume":"119","author":"Carlring","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0290","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ijc.11612","article-title":"Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand","volume":"108","author":"Huang","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0295","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2006-06-032938","article-title":"Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences","volume":"110","author":"Fredriksen","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2015.08.001_bib0300","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","article-title":"Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study","volume":"113","author":"Di Nicola","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0310","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2249.2012.04658.x","article-title":"Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma","volume":"170","author":"Manzur","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0315","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2007-03-080507","article-title":"Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo","volume":"111","author":"Franki","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0320","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20011097","article-title":"Antitumor monoclonal antibodies enhance cross-presentation of ular antigens and the generation of myeloma-specific killer T s by dendritic cells","volume":"195","author":"Dhodapkar","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2015.08.001_bib0325","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenco","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.08.001_bib0330","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","article-title":"Long-lasting anti-tumor protection by anti-CD20 antibody through cellular immune response","volume":"116","author":"Abes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0335","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-010-0918-x","article-title":"Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells","volume":"60","author":"Warncke","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"April","key":"10.1016\/j.leukres.2015.08.001_bib0345","first-page":"26","article-title":"CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma","author":"H\u00f6mberg","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0350","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1182\/blood-2012-04-426643","article-title":"NKT cell adjuvant-based tumor vaccine for treatment of myconcogene-driven mouse B-cell lymphoma","volume":"120","author":"Mattarollo","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2015.08.001_bib0355","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ijc.20170","article-title":"Serologic detection of diffuse large B-cell lymphoma-associated antigens","volume":"110","author":"Liggins","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0360","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00277-009-0711-0","article-title":"Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens","volume":"88","author":"Zwick","year":"2009","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2015.08.001_bib0365","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2011-09-379982","article-title":"Cancer\/testis antigens are novel targets of immunotherapy for adult T-cell leukemia\/lymphoma","volume":"119","author":"Nishikawa","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0370","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/1471-2407-11-416","article-title":"An overview of cancer\/testis antigens expression in classical Hodgkin\u2019s lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients","volume":"11","author":"Inaoka","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0375","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00262-012-1239-z","article-title":"Hodgkin\u2019s lymphoma RNA-transfected dendritic cells induce cancer\/testis antigen-specific immune responses","volume":"61","author":"Winkler","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0380","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.370.11.1","article-title":"CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma","volume":"11","author":"Palomba","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0385","doi-asserted-by":"crossref","first-page":"e77375","DOI":"10.1371\/journal.pone.0077375","article-title":"Targeting c-MYC with T-Cells","volume":"8","author":"Helm","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.leukres.2015.08.001_bib0390","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0395","first-page":"89","article-title":"Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?","volume":"1816","author":"Khalil","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2015.08.001_bib0400","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1182\/blood-2011-06-364570","article-title":"Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target","volume":"118","author":"Zappasodi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0405","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood-2011-09-382838","article-title":"TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas","volume":"120","author":"Weng","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0410","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1158\/1078-0432.CCR-12-0763","article-title":"IGKV3 proteins as candidate off-the-shelf vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas","volume":"18","author":"Martorelli","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0415","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-1-4939-0345-0_30","article-title":"Idiotype vaccine production using hybridoma technology","volume":"1139","author":"Inoges","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0420","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/157488706775246120","article-title":"Clinical benefit of idiotype vaccines: too many trials for a clever demonstration?","volume":"1","author":"Bendandi","year":"2006","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.leukres.2015.08.001_bib0425","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrc2717","article-title":"Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures","volume":"9","author":"Bendandi","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0430","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","article-title":"Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma","volume":"98","author":"Inog\u00e8s","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2015.08.001_bib0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3816\/CLM.2005.n.031","article-title":"Phase III. Randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report","volume":"6","author":"Neelapu","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.leukres.2015.08.001_bib0440","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0445","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0450","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.leukres.2015.08.001_bib0455","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1182\/blood-2009-01-201988","article-title":"Anti-idiotype antibody response after vaccination correlates with overall survival in follicular lymphoma","volume":"113","author":"Ai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0460","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/bbmt.2001.v7.pm11669219","article-title":"Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma","volume":"7","author":"Davis","year":"2001","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.leukres.2015.08.001_bib0465","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","article-title":"Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials","volume":"142","author":"Park","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0470","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood-2010-06-288456","article-title":"A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors","volume":"117","author":"Goldstein","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0475","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.21036","article-title":"Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond","volume":"83","author":"Zhou","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0480","doi-asserted-by":"crossref","first-page":"7750","DOI":"10.1038\/sj.onc.1207048","article-title":"Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase","volume":"22","author":"Turner","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2015.08.001_bib0485","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","article-title":"NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors","volume":"101","author":"Chiarle","year":"2003","journal-title":"Blood"},{"issue":"5A","key":"10.1016\/j.leukres.2015.08.001_bib0490","first-page":"3275","article-title":"CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy","volume":"26","author":"Turner","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0495","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1535-7163.MCT-11-0042","article-title":"Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools","volume":"10","author":"Merkel","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2015.08.001_bib0500","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nm1769","article-title":"The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination","volume":"14","author":"Chiarle","year":"2008","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0505","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2015.08.001_bib0510","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0515","first-page":"s56","article-title":"Patient-specific dendritic cell immunization against tumor in Sezary syndrome","volume":"130","author":"Geskin","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.leukres.2015.08.001_bib0520","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0525","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0530","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2011-09-379982","article-title":"Cancer\/testis antigens are novel targets of immunotherapy for adult T-cell leukemia\/lymphoma","volume":"119","author":"Nishikawa","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.08.001_bib0535","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1200\/JCO.2011.35.8812","article-title":"Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine","volume":"29","author":"Ansell","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0540","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1200\/JCO.2011.38.6094","article-title":"Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2015.08.001_bib0545","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2174\/156802611796117676","article-title":"Stem cell transplant and idiotypic vaccination for B-cell malignancies","volume":"11","author":"Inoges","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.leukres.2015.08.001_bib0550","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0555","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V95.10.3011","article-title":"Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines","volume":"95","author":"Borrello","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.08.001_bib0560","first-page":"162","article-title":"Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation","volume":"61","author":"Teshima","year":"2001","journal-title":"Cancer Res."},{"issue":"37","key":"10.1016\/j.leukres.2015.08.001_bib0565","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"Ho","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.leukres.2015.08.001_bib0570","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1172\/JCI69098","article-title":"Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells","volume":"123","author":"Burkhardt","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0575","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2011.06.011","article-title":"Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"18","author":"Holman","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"December (12)","key":"10.1016\/j.leukres.2015.08.001_bib0580","first-page":"e27058","article-title":"Combining low-dose or metronomic chemotherapy with anticancer vaccines. A therapeutic opportunity for lymphomas","volume":"2","author":"Sow","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2015.08.001_bib0585","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0590","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0595","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II. Clinical trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin\u2019s lymphoma resulting in durable clinical responses","volume":"24","author":"Redfern","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0600","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.leukres.2015.08.001_bib0605","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2006-11-057216","article-title":"Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation","volume":"109","author":"French","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2015.08.001_bib0610","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2005.02.005","article-title":"The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling","volume":"231","author":"Met","year":"2006","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.leukres.2015.08.001_bib0620","doi-asserted-by":"crossref","first-page":"e19499","DOI":"10.1371\/journal.pone.0019499","article-title":"Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production","volume":"6","author":"Curran","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.leukres.2015.08.001_bib0625","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.20082205","article-title":"OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis","volume":"206","author":"Hirschhorn-Cymerman","year":"2009","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.leukres.2015.08.001_bib0630","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-14-0019-T","article-title":"Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes","volume":"2","author":"Jeanbart","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.leukres.2015.08.001_bib0635","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.leukres.2012.10.003","article-title":"A therapeutic vaccine using Salmonella-modified tumor s combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma","volume":"37","author":"Grille","year":"2013","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0640","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2011.06.008","article-title":"An injectable synthetic immune-priming center mediates efficient T- class switching and T-helper 1 response against B cell lymphoma","volume":"155","author":"Singh","year":"2011","journal-title":"J Control. Release"},{"key":"10.1016\/j.leukres.2015.08.001_bib0645","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","article-title":"Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy","volume":"224","author":"Peggs","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2015.08.001_bib0650","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1078-0432.CCR-06-1974","article-title":"A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy","volume":"13","author":"O\u2019Mahony","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0655","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0660","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I. Safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"15S","key":"10.1016\/j.leukres.2015.08.001_bib0665","article-title":"University of Texas M. D. Anderson Cancer Center, Houston, TX; CureTech, Yavne, Israel Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma","volume":"28","author":"Westin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"suppl","key":"10.1016\/j.leukres.2015.08.001_bib0670","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/jco.2008.26.15_suppl.3006","article-title":"Lowy safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies","volume":"28","author":"Brahmer","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"75","key":"10.1016\/j.leukres.2015.08.001_bib0675","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pep.2010.09.005","article-title":"Escherichia coli-based production of a tumor idiotype antibody fragment\u2014tetanus toxin fragment C fusion protein vaccine for B cell lymphoma","volume":"2011","author":"Patel","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.leukres.2015.08.001_bib0680","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.vaccine.2008.10.055","article-title":"Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells","volume":"27","author":"Betting","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.leukres.2015.08.001_bib0685","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1158\/1078-0432.CCR-04-1071","article-title":"Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen","volume":"10","author":"Neelapu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0690","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/emm.2013.14","article-title":"is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells","volume":"45","author":"Park","year":"2013","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.leukres.2015.08.001_bib0695","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3109\/10428194.2011.577257","article-title":"Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response againstlymphoma in human leukocyte antigen-A2.1 transgenic mice","volume":"52","author":"Liu","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0700","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2011.02.001","article-title":"Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma","volume":"62","author":"Schlapbach","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.leukres.2015.08.001_bib0705","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2015.08.001_bib0710","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.leukres.2014.08.004","article-title":"Allergy and risk of hematologic malignancies: associations and mechanisms","volume":"38","author":"Musolino","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.08.001_bib0715","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2015.02.002","article-title":"Lymphoproliferative disease and cancer among patients with common variable immunodeficiency","volume":"39","author":"Gangemi","year":"2015","journal-title":"Leuk. Res."},{"issue":"15","key":"10.1016\/j.leukres.2015.08.001_bib0720","first-page":"121","article-title":"Vaccination of multiple myeloma: current strategies and future prospects","volume":"S1040\u20138428","author":"Allegra","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0725","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molonc.2012.01.002","article-title":"Cancer immunotherapy","volume":"6","author":"Gajewski","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0730","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2015.08.001_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2015.08.001_bib0740","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2015.08.001_bib0745","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nri1919","article-title":"Tumour-induced immune modulation of sentinel lymph nodes","volume":"6","author":"Cochran","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0750","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2015.08.001_bib0755","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2011.03.007","article-title":"Translational development of vaccination strategies in follicular NHL","volume":"24","author":"Sakamaki","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2015.08.001_bib0760","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/hv.23970","article-title":"Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas","volume":"9","author":"Muraro","year":"2013","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615303544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615303544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:31:25Z","timestamp":1718019085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615303544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":152,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0145212615303544"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.08.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination strategies in lymphoproliferative disorders: Failures and successes","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}